QUINTA-ANALYTICA, as part of Conscio Group, along with our network of companies, is looking forward to reconnecting with our current partners and friends, as well as establishing new collaborations at the pharmaceutical event of the year.

Visit us at the Conscio Group booth 22G4 in the Integrated Pharma Hall to explore how our combined expertise can drive drug development in innovative formulations, pharmaceutical research, analytical solutions for pharmaceuticals and biologics, and clinical development, including trials and bioanalysis.

You’ll also have the opportunity to meet our strategic partner, Kiel Laboratories, based in USA, who specializes in supporting pharmaceutical companies in bringing new drugs to market, particularly through the 505(b)(2) process of the US-FDA approval.

If you’re interested in arranging a meeting with us, please reach out to your business representative or send an email to sales@quinta.cz, and we will schedule a time slot for you.

Additional News

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.